Latest news with #autoimmunity
Yahoo
14 hours ago
- Business
- Yahoo
How Is Incyte's Stock Performance Compared to Other Biotech Stocks?
With a market cap of $13.3 billion, Incyte Corporation (INCY) is a global biopharmaceutical company focused on discovering, developing, and commercializing therapies in oncology, inflammation, and autoimmunity. The Wilmington, Delaware-based company has over 2,600 employees and a manufacturing and R&D footprint across North America, Europe, and Asia. Companies valued at $10 billion or more are generally labelled as 'large-cap' stocks, and Incyte fits this criterion perfectly. Its leadership stems from its strong portfolio of high-demand specialty drugs, notably Jakafi and Opzelura, which serve as key revenue drivers in the oncology and dermatology markets. Its robust research and development capabilities, with a diverse and advancing pipeline targeting cancer, inflammation, and autoimmune diseases, position it for long-term innovation. The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon. Warren Buffett's Berkshire Hathaway Now Pays 5% of All Corporate Income Taxes in America Meta's Mark Zuckerberg Says the Technology They're Developing Will 'See What You See and Hear What You Hear' Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Despite that, INCY has fallen 19.9% from its 52-week high of $83.95, achieved on Nov. 8. Yet, shares of INCY have risen 8.6% over the past three months, compared to the SPDR S&P Biotech ETF's (XBI) 5.6% fall during the same time frame. INCY is down 2.6% on a YTD basis, lagging behind XBI's 8.7% gains. However, shares of Incyte have climbed 6.4% over the past 52 weeks, compared to XBI's 10.9% fall over the same time frame. INCY has been trading above its 200-day moving average since early June and has mostly stayed above its 50-day moving average since mid-May. On June 16, shares of Incyte rose more than 4% following the announcement of encouraging clinical trial results for its investigational therapy targeting a blood disorder. The company reported positive data from two separate studies, which demonstrated the treatment's potential effectiveness and safety in managing the condition, likely a form of myeloproliferative neoplasm or a related hematologic disease. The strong outcomes from these trials bolstered investor confidence in the strength of Incyte's R&D pipeline and its ability to diversify beyond its flagship drug, Jakafi. In comparison, rival Exelixis, Inc. (EXEL) outperformed INCY. Shares of Exelixis have gained 95.4% over the past 52 weeks and 30.2% on a YTD basis. Among the 25 analysts covering the stock, there is a consensus rating of 'Moderate Buy,' and its mean price target of $75.81 indicates an upswing potential of 12.7% from the prevailing price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Medscape
6 days ago
- Health
- Medscape
Azacitidine Shows Promise in Treating VEXAS Syndrome
Azacitidine showed potential in treating patients with VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, offering high response rates and reducing the use of glucocorticoids. Tocilizumab and anakinra also demonstrated effectiveness, with a higher discontinuation rate seen with the latter. METHODOLOGY: Researchers conducted a retrospective cohort study in the UK and analyzed 71 treatment courses in 59 patients with genetically confirmed VEXAS syndrome (mean age at treatment initiation, 71 years; 98% men) across six major tertiary referral centers from July 2014 to October 2024. Patients received five categories of targeted therapy: Tocilizumab (n = 19), anakinra (n = 13), azacitidine (n = 13), baricitinib (n = 11), and prednisolone alone (n = 10). Data were collected at diagnosis, treatment initiation, and follow-ups at 3 months, 6 months, and 12 months. Primary outcomes were complete response (defined as clinical remission with a C-reactive protein level ≤ 10 mg/L and requirement of ≤ 10 mg/d prednisolone) and partial response (defined as clinical remission with at least a 50% reduction in both C-reactive protein level and glucocorticoid dose from baseline). Adverse events and treatment discontinuation were documented, with serious events defined as those requiring permanent discontinuation. The study followed methods used in a French cohort study with adjustments to only the statistical reporting format to enable comparisons. TAKEAWAY: Azacitidine showed a 91% overall response rate at 6 months (10 of 11 patients), with 27% of patients achieving complete response, and maintained effectiveness at 12 months. Glucocorticoid-sparing effects were notable with prednisolone doses reduced to ≤ 5 mg/d in 60% of patients on azacitidine at 12 months. Anakinra showed promising initial responses at 3 months (seven of eight patients), with a 100% response rate at 6 months in those who tolerated it (n = 3); however, the discontinuation rate was high due to severe injection-site reactions. Tocilizumab had a 64% response rate at 6 months (seven of 11 patients), with 36% of patients achieving complete response, whereas baricitinib showed modest effectiveness, with the highest mortality at 27%. Adverse events were documented for 54% of the therapies, with infections being the most common events, particularly noted with azacitidine (62%) and tocilizumab (47%). IN PRACTICE: 'The findings of this study provide important real-world evidence to guide clinical practice and future research directions in management of patients with VEXAS syndrome,' the authors wrote. SOURCE: This study was led by Adam Al-Hakim, BMBS, Leeds Institute for Rheumatic and Musculoskeletal Medicine, Leeds, England. It was published online on May 21, 2025, in The Lancet Rheumatology . LIMITATIONS: The sample size was small, which affected the ability to conduct multivariable analyses, thereby affecting the assessment of treatment effectiveness. Clinical response was based on physician opinion, increasing reporting bias and variance. The lack of standardized prednisolone tapering protocols could have influenced response assessments. DISCLOSURES: No funding was received for this study. Some authors disclosed receiving honoraria, grants, travel support, and consulting fees from various pharmaceutical companies, including AstraZeneca and Novartis. One author reported receiving support for meetings, projects, advisory boards, and clinical trials from various sources.
Yahoo
09-06-2025
- Business
- Yahoo
Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025
LUND, Sweden, June 9, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual investor event on Guillain-Barré syndrome (GBS) on Monday, June 16, 2025 at 14:00 CEST / 8:00 AM EDT. Pre-registration is required and can be found at this link. Presentations by Dr. David R. Cornblath, MD, Johns Hopkins University School of Medicine and Dr. Simon Rinaldi MRCP (Neuro), PhD, University of Oxford will discuss the unmet need and current treatment landscape for GBS, an acute, rare, paralyzing inflammatory disease of the peripheral nervous system, as well as the role of Immunoglobulin G (IgG) in GBS and recent advancements in science and research. Company management including Hitto Kaufmann, Chief R&D Officer, and Elisabeth Sonesson, VP, Global Franchise Lead Autoimmunity, will highlight current activities and anticipated milestones for the Company in the autoimmune space. A live Q&A will follow the presentations. This is the first in a series of Science Deep Dive virtual events specifically aimed for the investor community and focusing on Hansa's disease areas - Autoimmune, Gene Therapy, and Kidney Transplantation. About David R. Cornblath, MD Dr. David Cornblath received his medical degree from Case Western Reserve University, completed an internship at University Hospitals in Cleveland, Ohio, and neurology residency at the Hospital of the University of Pennsylvania. He served as Clinical Fellow of the Muscular Dystrophy Association at the Peripheral Nerve Morphology Laboratory and then joined the Faculty at Johns Hopkins, rising to rank of Professor and serving as Director of the Neurology EMG Laboratory. Currently retired, Dr. Cornblath continues to consult, serving on safety monitoring boards and clinical trial development programs. He also holds the title of Professor Emeritus of Neurology at Johns Hopkins. About Simon Rinaldi, MRCP(Neuro), PhD Dr. Simon Rinaldi is a clinician scientist and clinical neurologist who leads the University of Oxford's programme of inflammatory neuropathy research. This research spans from in vitro disease modelling using cell-based assays to biomarker discovery, clinical phenotyping, and clinical trials. His lab has developed models of immune mediated axonal injury and demyelination using human induced pluripotent stem cell derived myelinating co-cultures. These experimental systems are now being used to learn more about the mechanisms of immune-mediated peripheral nerve injury, and are a valuable tool in the search for novel auto-antibodies and for the discovery and pre-clinical evaluation of fluid biomarkers. The lab also runs the only UK based diagnostic testing service for nodal and paranodal antibodies, which associate with distinct forms of autoimmune nodopathy, and the underlying B-cell biology of these and related peripheral nerve disorders is a more recent area of study. His research programme also includes a clinical / observational study of chronic inflammatory neuropathy (Bio-SPiN). The group additionally contributes to and benefits from close links with the comprehensive and high-quality clinical-serological database of 2000 patients encapsulated in the International GBS Outcome Study (IGOS) and has been involved in therapeutic trials in Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and multifocal motor neuropathy (MMN). Conference call details To register and to submit questions in advance, please use the following link: To participate in the telephone conference, please use the dial-in details provided below: Participant Dial In (Toll Free): 1-833-821-3542 Participant International Dial In: 1-412-652-1248 The webcast will be available on: Contacts for more information: Evan Ballantyne, Chief Financial OfficerIR@ Stephanie Kenney, VP Global Corporate Affairsmedia@ Notes to editors About Hansa Biopharma Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at and follow us on LinkedIn. ©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved. This information was brought to you by Cision The following files are available for download: 250609 - HNSA Autoimmune Deep Dive 16 June 2025 View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
